News & Media
TheraCell and AlloSource Announce Issuance of Patent for Bone Fiber Technology
Northridge, Calif. and Centennial, Colo. — Oct. 25, 2016 — TheraCell, a regenerative medicine company, today announced that the United States Patent and Trademark Office (USPTO) will issue TheraCell a patent for its demineralized bone fiber (DBF™) technology. The addition of this patent expands TheraCell’s patent portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry. (Read More)
Theracell, Inc. (Los Angeles) announces appointment of Dr. Gunnar Andersson to its Board of Directors and Surgeon Advisory Board.
LOS ANGELES, May 21, 2015 — The Board of Directors of Theracell, Inc. today announced the appointment of Dr. Gunnar B.J. Andersson, MD PhD, a world-renowned spine surgeon as a director of the company and member of the its surgeon advisory board, effective immediately. Dr. Andersson’s appointment expands the Board to 5 directors. Two of the company’s five directors are spine surgeons. (Read More)
Acquisition of VET-INC
February 12, 2015 -- TheraCell announces that it has acquired the assets of VET-INC a veterinary orthobiologics company. TheraCell-VET will be a division of TheraCell that will develop, manufacture and market products aimed at the veterinary orthopedic market.
Nelson Scarborough PhD appointed as Chief Scientific Officer
January 4, 2015 -- TheraCell announces that Nelson Scarborough PhD, an acknowledged expert in the field of orthobiologics and allograft tissue technologies has been appointed as Chief Scientific Officer of TheraCell inc.
Oxygenated DBM US Patent Granted
October 14, 2014 -- TheraCell announces that it has received a notice of allowance for US Patent 8,859,007, “Oxygenated Demineralized Bone Matrix for Bone Growth”.
Nelson Scarborough to present “Novel Tissue-Engineered structures made from Demineralized Bone Fibers” at Spine Technology Education Group Meeting in Los Cabos, Mexico June 2014
June 1, 2014 -- TheraCell announces that Nelson Scarborough, Vice President of Product development is to present on TheraCell’s proprietary demineralized bone fiber (DBFTM) technology at the Spine Technology Education Group meeting in Los Cabos, Mexico.
TheraCell enters License and Development Agreement with a large US tissue bank
December 12, 2013 -- TheraCell announces that it has entered into a license and development agreement with a large US tissue bank. Under terms of the agreement they will manufacture and distribute products based on TheraCell’s proprietary demineralized bone fiber (DBF™), and Enhanced Cancellous Bone™ technology platforms.
TheraCell establishes Laboratory in Massachusetts
November 1, 2013 -- TheraCell announces that it has established a laboratory in the M2D2 incubator at UMASS Lowell.
Andy Carter to present “Novel Biologics Platform with Enhanced Outcomes” at Spine Technology Education Group Meeting in Los Cabos, Mexico June 2013
June 1, 2013 -- Andy Carter PhD, Chief Technology Officer is to present on TheraCell’s proprietary oxygenated demineralized bone technology at the Spine Technology Education Group meeting in Los Cabos, Mexico.
JERUSALEM -- (BUSINESS WIRE) -- July 14, 2009 07:00 AM EDT -- Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has licensed a novel package of stem cell related technologies to TheraCell, Inc. (California, USA), which will further develop and commercialize the technology for advanced regenerative medicine procedures such as spinal fusion. The technology was invented by a team headed by Professor Dan Gazit from the Faculty of Dental Medicine at the Hebrew University of Jerusalem. (Read More)